ClinicalTrials.gg
CompletedNCT04488133RESPONDUpdated Oct 30, 2026Results posted

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

A Phase 4 interventional study of Nusinersen in Muscular Atrophy, Spinal, sponsored by Biogen. Completed at 15 sites in 5 countries. Open to participants aged 2 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Biogen · Phase 4, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
2 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing nusinersen in Muscular Atrophy, Spinal — 3 open to participants now, 4 under way, 2 of them phase 3. nusinersen · Muscular Atrophy, Spinal.

Enrollment
8th of 19
46 · median 34
Started
2021
with 1 other
Phase 4
Only one
of the 19
Registered
13th of 19
by date
Lead sponsor
15 of 19
Biogen

Among the 19 studies testing nusinersen in Muscular Atrophy, Spinal, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 4, and was the 13th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

3 of the 19 studies testing nusinersen in Muscular Atrophy, Spinal are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nusinersen

nusinersen: first FDA approval 2016 (SPINRAZA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 2 Months to 36 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nusinersen in Muscular Atrophy, Spinal, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the use of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on children under the age of 3 who were previously treated with the gene therapy onasemnogene abeparvovec but are still facing health challenges related to their disease.

The main goal of the study is to learn about the effect nusinersen has on muscle and movement ability (motor function). The main question researchers want to answer is:

- What score do participants have on the HINE Section 2 Motor Milestones test after treatment?

The Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones is an assessment that tests movements in different positions. This includes grasping, kicking, head control, rolling, sitting, crawling, standing, and walking.

Researchers will use a group of tests to study body movements, reflexes, balance, and coordination. They will also record if participants need help with breathing.

Researchers will also learn more about the safety of nusinersen. They will check participants for adverse events and changes in vital signs, heart tests, and laboratory tests including blood and urine tests.

The study will be done as follows:

  • Participants will be screened to check if they can join the study.
  • Each participant will receive 4 initial doses of 12 mg of nusinersen on Days 1, 15, 29, and 64 of the Treatment Period. Then, they will receive 12 mg doses once every 4 months.
  • The total number of doses of nusinersen will be 9.
  • Nusinersen will be given through a lumbar puncture, which involves injecting the drug into the fluid around the spinal cord in the lower back.
  • The treatment period will last for up to 95 weeks (close to 2 years).
  • There will be a follow-up safety period that lasts about 4 months.
  • In total, participants will have up to 14 study visits. Participants will stay in the study for up to 115 weeks.
Read the detailed description

The primary objective of this study is to evaluate the clinical outcomes following treatment with nusinersen in participants with spinal muscular atrophy (SMA) who previously received onasemnogene abeparvovec.

The secondary objectives of this study are to evaluate the safety and tolerability; clinical outcomes and pharmacodynamics (PD) of nusinersen treatment in participants with SMA who previously received onasemnogene abeparvovec.

03

Conditions studied

  • Muscular Atrophy, Spinal
04

Who can participate

Ages eligible
2 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

For all participants:

  • Genetic documentation of 5q SMA homozygous gene survival motor neuron 1 (SMN1) deletion or mutation, or compound heterozygous mutation
  • SMN2 copy number of ≥1
  • ≤36 months of age at the time of first Nusinersen dose
  • Must have previously received onasemnogene abeparvovec per the approved label or local/regional regulations ≥2 months prior to first Nusinersen dose
  • Must have suboptimal clinical status per the Investigator

Additional Criteria for Subgroups A and B:

  • \<300 days of age at the time of first Nusinersen dose
  • SMN2 copy number of 2

Additional Criteria for Subgroup A:

  • SMA symptom onset ≤4 months (120 days) of age
  • Must have received intravenous (IV) onasemnogene abeparvovec at >6 weeks to ≤6 months (43 days to 180 days) of age
  • Must have received IV onasemnogene abeparvovec after SMA symptom onset

Additional Criteria for Subgroup B:

  • Must have received IV onasemnogene abeparvovec at ≤6 weeks (42 days) of age

Key Exclusion Criteria:

For all participants:

  • Prior exposure to Nusinersen
  • Ongoing severe or serious AEs related to onasemnogene abeparvovec
  • Treatment with an drug, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to study; any prior or current treatment with any survival motor neuron 2 (SMN2)-directed splicing modifier; prior antisense oligonucleotide treatment or cell transplantation; gene therapy for the treatment of SMA other than onasemnogene abeparvovec. Note: treatment with onasemnogene abeparvovec as part of an investigational study is allowed

Additional Criteria for Subgroups A and B:

  • Weight-for-age is below the third percentile, based on WHO Child Growth Standards at the time of receiving onasemnogene abeparvovec. Adjustments for the gestational weight of premature babies enrolled in Subgroups A and B are allowed provided IV onasemnogene abeparvovec was dosed per the approved label or per local/regional regulations.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Nusinersen 12 mg

    Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.

    Drug: Nusinersen

Interventions

  • Administered as specified in the treatment arm.

    Also known as: ISIS 396443, BIIB058, Spinraza

06

What researchers measure

Primary outcomes

  1. Total Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score

    Section 2 of the HINE was used to assess motor milestones of the participants. It is composed of 8 motor milestone categories: voluntary grasp, ability to kick in supine position, head control, rolling, sitting, crawling, standing, and walking. Within each category, 3 to 5 levels can be achieved. Total HINE section 2 motor milestones score was calculated as the sum of each level and can range from 0 to 26. A higher score indicated good neurological function.

    Time frame: Up to Day 778

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death; placed the participant at immediate risk of death (according to the investigator's judgment); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a birth defect or was a medically important event.

    Time frame: From first dose of study drug up to end of study (up to Day 778)

  2. Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Haematology Parameters)

    Hematology parameters included hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, neutrophils, eosinophils, basophils, lymphocytes and monocytes count. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values.

    Time frame: Baseline up to Day 778

  3. Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)

    Blood chemistry parameters included bilirubin, direct and indirect bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, creatinine, urea nitrogen, cystatin C, sodium, potassium, chloride, bicarbonate, protein, albumin, calcium, phosphate, glucose, and creatine kinase. These parameters were flagged as low, normal, or high relative to the parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Day 778

  4. Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Coagulation Parameters)

    Coagulation parameters included activated partial thromboplastin time, prothrombin international (Intl.) normalized ratio and prothrombin time. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Day 778

  5. Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)

    Urinalysis included assessments of specific gravity, pH, protein, glucose, ketones, direct bilirubin, occult blood, erythrocytes, leukocytes, epithelial cells, transitional epithelial cells, hyaline casts, ammonium biurate, amorphous crystals, calcium oxalate crystals, triple phosphate crystals and uric acid crystals. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Day 778

  6. Number of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECGs)

    Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values postbaseline.

    Time frame: Baseline up to Day 778

  7. Number of Participants With Abnormalities in Vital Signs

    Vital sign assessment included temperature, heart rate, systolic blood pressure, and diastolic blood pressure. As pre-specified in SAP, the criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \> 38.0 degrees Celsius (C), heart rate increments or decrements of 15 and 30 beats per minute (bpm), systolic blood pressure increments or decrements of 20 and 40 \[millimeters of mercury (mmHg)\], diastolic blood pressure increments or decrements of 10 and 20 mmHg. The categories with at least one participant with clinically relevant vital sign abnormalities are reported.

    Time frame: Up to Day 778

  8. Number of Participants Who Achieved Motor Milestones as Assessed by World Health Organization (WHO) Criteria

    The WHO motor milestones were a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone.

    Time frame: Day 778

  9. Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score

    The CHOP-INTEND test was designed to evaluate the motor skills of infants with significant motor weakness. It was evaluated for participants \< 2 years of age at the time of informed consent and for participants 2 to ≤ 3 years of age at the time of informed consent if they did not achieve independent sitting prior to Screening. It included 16 items (capturing neck, trunk, and proximal and distal limb strength), nine of which were scored 0, 1, 2, 3, or 4 with greater scores indicating greater muscle strength, five were scored as 0, 2, or 4, one was scored as 0, 1, 2, or 4, and one as 0, 2, 3, or 4. Total score was calculated as the sum of scores for each item. Total score ranged from 0 (worst possible score) and 64 (best possible score). CHOP-INTEND assessments were discontinued once participants achieved a maximum score of 64 after Day 421, so the number of participants with data points decreased over time.

    Time frame: Baseline, Day 778

  10. Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score

    The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. It was assessed only in participants aged 2 years and older. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0 = being unable, 1 = performed with some compensation, and 2 = unaided. The overall score is the sum of the scores for all activities and ranged from 0 to 66. Higher scores indicated increased motor function.

    Time frame: Baseline, Day 778

  11. Change From Baseline in Revised Upper Limb Module (RULM) Score

    RULM test was developed to assess upper limb functional abilities. It was assessed only in participants aged 2 years and older. RULM test: total 19 items. 18 items were assessed on 3-point scale: 0-Unable to achieve independently; 1-Modified method but achieves goal independent of physical assistance from another person; 2-Normal -achieves goal without any assistance. One remaining item was assessed as either 0 or 1. For each item, score was collected on left \& right side. Derived total score=summing scores from these 19 individual items ranging from 0-if participant fails all activities to 37-if participant achieves all activities. If, for an individual item, response was recorded for both left \& right side, highest score was used in calculating total score. Higher scores=increased upper limb function.

    Time frame: Baseline, Day 778

  12. Time to Death or Permanent Ventilation

    Time to death or permanent ventilation is defined as the time from first dose to death or permanent ventilation (tracheostomy or 16 hours of ventilation/day continuously for \> 21 days in the absence of an acute reversible event), whichever comes first. Time to death or permanent ventilation was estimated using the Kaplan-Meier method.

    Time frame: Up to Day 778

  13. Change From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)

    The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.

    Time frame: Baseline, Day 659

  14. Change From (Ratio to) Baseline in Plasma Levels of NF-L

    The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.

    Time frame: Baseline, Day 778

07

Results

Posted Oct 30, 2026

Participant flow

Participants took part at multiple investigative sites from 04 January 2021 to 09 October 2025.

Participant flow — Overall Study
MilestoneNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Started424
Completed353
Not completed71
Withdrew: Death10
Withdrew: Protocol deviation10
Withdrew: Withdrawal by parent and guardian50
Withdrew: Lost to follow-up01

Outcome measures

PrimaryTotal Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score

Section 2 of the HINE was used to assess motor milestones of the participants. It is composed of 8 motor milestone categories: voluntary grasp, ability to kick in supine position, head control, rolling, sitting, crawling, standing, and walking. Within each category, 3 to 5 levels can be achieved. Total HINE section 2 motor milestones score was calculated as the sum of each level and can range from 0 to 26. A higher score indicated good neurological function.

Time frame:
Up to Day 778
Reported as:
Mean · score on a scale
Total Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score
score on a scaleNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Day 14.6 ± 4.0515.3 ± 7.89
Day 647.0 ± 5.1818.00 ± 6.00
Day 18310.1 ± 5.5017.5 ± 6.61
Day 30212.8 ± 5.2518.3 ± 5.13
Day 42113.6 ± 5.3220.0 ± 5.29
Day 54014.5 ± 6.0822.0 ± 4.00
Day 65916.4 ± 5.6521.3 ± 4.16
Day 77817.0 ± 5.6821.7 ± 2.89
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death; placed the participant at immediate risk of death (according to the investigator's judgment); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a birth defect or was a medically important event.

Time frame:
From first dose of study drug up to end of study (up to Day 778)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
AEs394
SAEs242
SecondaryNumber of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Haematology Parameters)

Hematology parameters included hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, neutrophils, eosinophils, basophils, lymphocytes and monocytes count. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values.

Time frame:
Baseline up to Day 778
Reported as:
Count of participants · Participants
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Haematology Parameters)
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Hemoglobin: Shift to Low40
Hemoglobin: Shift to High20
Hematocrit: Shift to Low10
Hematocrit: Shift to High70
Erythrocytes: Shift to Low00
Erythrocytes: Shift to High40
Leukocytes: Shift to Low60
Leukocytes: Shift to High172
Neutrophils: Shift to Low121
Neutrophils: Shift to High82
Neutrophils/Leukocytes: Shift to Low220
Neutrophils/Leukocytes: Shift to High11
Eosinophils/Leukocytes: Shift to Low00
Eosinophils/Leukocytes: Shift to High163
Basophils/Leukocytes: Shift to Low00
Basophils/Leukocytes: Shift to High183
Lymphocytes/Leukocytes: Shift to Low11
Lymphocytes/Leukocytes: Shift to High190
Monocytes/Leukocytes: Shift to Low172
Monocytes/Leukocytes: Shift to High50
Basophils: Shift to Low00
Basophils: Shift to High163
Lymphocytes: Shift to Low00
Lymphocytes: Shift to High231
Monocytes: Shift to Low60
Monocytes: Shift to High111
Eosinophils: Shift to Low10
Eosinophils: Shift to High132
Platelets: Shift to Low10
Platelets: Shift to High110
SecondaryNumber of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)

Blood chemistry parameters included bilirubin, direct and indirect bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, creatinine, urea nitrogen, cystatin C, sodium, potassium, chloride, bicarbonate, protein, albumin, calcium, phosphate, glucose, and creatine kinase. These parameters were flagged as low, normal, or high relative to the parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Day 778
Reported as:
Count of participants · Participants
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Bilirubin: Shift to Low10
Bilirubin: Shift to High00
Indirect Bilirubin: Shift to Low292
Indirect Bilirubin: Shift to High00
Alkaline Phosphatase: Shift to Low00
Alkaline Phosphatase: Shift to High71
Alanine Aminotransferase: Shift to Low00
Alanine Aminotransferase: Shift to High120
Aspartate Aminotransferase: Shift to Low00
Aspartate Aminotransferase: Shift to High40
Gamma Glutamyl Transferase: Shift to Low20
Gamma Glutamyl Transferase: Shift to High00
Urea Nitrogen: Shift to Low20
Urea Nitrogen: Shift to High51
Cystatin C: Shift to Low30
Cystatin C: Shift to High00
Sodium: Shift to Low01
Sodium: Shift to High00
Potassium: Shift to Low00
Potassium: Shift to High111
Chloride: Shift to Low00
Chloride: Shift to High01
Bicarbonate: Shift to Low92
Bicarbonate: Shift to High10
Protein: Shift to Low10
Protein: Shift to High80
Calcium: Shift to Low21
Calcium: Shift to High120
Phosphate: Shift to Low00
Phosphate: Shift to High162
Glucose: Shift to Low51
Glucose: Shift to High170
Creatine Kinase: Shift to Low00
Creatine Kinase: Shift to High80
SecondaryNumber of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Coagulation Parameters)

Coagulation parameters included activated partial thromboplastin time, prothrombin international (Intl.) normalized ratio and prothrombin time. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Day 778
Reported as:
Count of participants · Participants
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Coagulation Parameters)
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Activated Partial Thromboplastin Time: Shift to Low50
Activated Partial Thromboplastin Time: Shift to High31
Prothrombin Intl. Normalized Ratio: Shift to Low00
Prothrombin Intl. Normalized Ratio: Shift to High31
Prothrombin Time: Shift to Low20
Prothrombin Time: Shift to High51
SecondaryNumber of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)

Urinalysis included assessments of specific gravity, pH, protein, glucose, ketones, direct bilirubin, occult blood, erythrocytes, leukocytes, epithelial cells, transitional epithelial cells, hyaline casts, ammonium biurate, amorphous crystals, calcium oxalate crystals, triple phosphate crystals and uric acid crystals. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Day 778
Reported as:
Count of participants · Participants
Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Specific Gravity: Shift to Low00
Specific Gravity: Shift to High30
pH: Shift to Low00
pH: Shift to High171
Protein All: (High/Positive (Pos)293
Glucose: High/Pos10
Ketones: High/Pos200
Direct Bilirubin: High/Pos10
Occult Blood: High/Pos70
Erythrocytes (/high power field [HPF]): High/Pos242
Leukocytes (/HPF): High/Pos232
Epithelial Cells: High/Pos30
Transitional Epithelial Cells: High/Pos50
Ammonium Biurate Crystals: High/Pos10
Amorphous Crystals: High/Pos210
Calcium Oxalate Crystals: High/Pos121
Triple Phosphate Crystals: High/Pos20
Uric Acid Crystals: High/Pos51
SecondaryNumber of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECGs)

Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values postbaseline.

Time frame:
Baseline up to Day 778
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECGs)
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Shift to abnormal, not adverse event161
Shift to abnormal, adverse event00
SecondaryNumber of Participants With Abnormalities in Vital Signs

Vital sign assessment included temperature, heart rate, systolic blood pressure, and diastolic blood pressure. As pre-specified in SAP, the criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \> 38.0 degrees Celsius (C), heart rate increments or decrements of 15 and 30 beats per minute (bpm), systolic blood pressure increments or decrements of 20 and 40 \[millimeters of mercury (mmHg)\], diastolic blood pressure increments or decrements of 10 and 20 mmHg. The categories with at least one participant with clinically relevant vital sign abnormalities are reported.

Time frame:
Up to Day 778
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Vital Signs
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Temperature >38 degrees C00
Heart rate Increment or decrement of 15 bpm423
Heart rate Increment or decrement of 30 bpm343
Systolic blood pressure Increment or decrement of 20 mmHg373
Systolic blood pressure Increment or decrement of 40 mmHg110
Diastolic blood pressure Increment or decrement of 10 mmHg414
Diastolic blood pressure Increment or decrement of 20 mmHg303
SecondaryNumber of Participants Who Achieved Motor Milestones as Assessed by World Health Organization (WHO) Criteria

The WHO motor milestones were a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone.

Time frame:
Day 778
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Motor Milestones as Assessed by World Health Organization (WHO) Criteria
ParticipantsNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Sitting without support — 1 - No Ability40
Sitting without support — 2- No (Refusal)00
Sitting without support — 3 - Yes323
Sitting without support — 9 - Unable to test00
Hands-and-Knees Crawling — 1 - No Ability311
Hands-and-Knees Crawling — 2- No (Refusal)00
Hands-and-Knees Crawling — 3 - Yes52
Hands-and-Knees Crawling — 9 - Unable to test00
Standing With Assistance — 1 - No Ability232
Standing With Assistance — 2- No (Refusal)00
Standing With Assistance — 3 - Yes131
Standing With Assistance — 9 - Unable to test00
Walking With Assistance — 1 - No Ability282
Walking With Assistance — 2- No (Refusal)00
Walking With Assistance — 3 - Yes81
Walking With Assistance — 9 - Unable to test00
Standing Alone — 1 - No Ability322
Standing Alone — 2- No (Refusal)00
Standing Alone — 3 - Yes41
Standing Alone — 9 - Unable to test00
Walking Alone — 1 - No Ability332
Walking Alone — 2- No (Refusal)00
Walking Alone — 3 - Yes31
Walking Alone — 9 - Unable to test00
SecondaryChange From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score

The CHOP-INTEND test was designed to evaluate the motor skills of infants with significant motor weakness. It was evaluated for participants \< 2 years of age at the time of informed consent and for participants 2 to ≤ 3 years of age at the time of informed consent if they did not achieve independent sitting prior to Screening. It included 16 items (capturing neck, trunk, and proximal and distal limb strength), nine of which were scored 0, 1, 2, 3, or 4 with greater scores indicating greater muscle strength, five were scored as 0, 2, or 4, one was scored as 0, 1, 2, or 4, and one as 0, 2, 3, or 4. Total score was calculated as the sum of scores for each item. Total score ranged from 0 (worst possible score) and 64 (best possible score). CHOP-INTEND assessments were discontinued once participants achieved a maximum score of 64 after Day 421, so the number of participants with data points decreased over time.

Time frame:
Baseline, Day 778
Reported as:
Mean · score on a scale
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score
score on a scaleNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Score14.7 ± 8.18—
SecondaryChange From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score

The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. It was assessed only in participants aged 2 years and older. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0 = being unable, 1 = performed with some compensation, and 2 = unaided. The overall score is the sum of the scores for all activities and ranged from 0 to 66. Higher scores indicated increased motor function.

Time frame:
Baseline, Day 778
Reported as:
Mean · score on a scale
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score
score on a scaleNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score7.0 ± 1.419.7 ± 2.08
SecondaryChange From Baseline in Revised Upper Limb Module (RULM) Score

RULM test was developed to assess upper limb functional abilities. It was assessed only in participants aged 2 years and older. RULM test: total 19 items. 18 items were assessed on 3-point scale: 0-Unable to achieve independently; 1-Modified method but achieves goal independent of physical assistance from another person; 2-Normal -achieves goal without any assistance. One remaining item was assessed as either 0 or 1. For each item, score was collected on left \& right side. Derived total score=summing scores from these 19 individual items ranging from 0-if participant fails all activities to 37-if participant achieves all activities. If, for an individual item, response was recorded for both left \& right side, highest score was used in calculating total score. Higher scores=increased upper limb function.

Time frame:
Baseline, Day 778
Reported as:
Mean · score on a scale
Change From Baseline in Revised Upper Limb Module (RULM) Score
score on a scaleNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Change From Baseline in Revised Upper Limb Module (RULM) Score13.0 ± NA8.0 ± 3.61
SecondaryTime to Death or Permanent Ventilation

Time to death or permanent ventilation is defined as the time from first dose to death or permanent ventilation (tracheostomy or 16 hours of ventilation/day continuously for \> 21 days in the absence of an acute reversible event), whichever comes first. Time to death or permanent ventilation was estimated using the Kaplan-Meier method.

Time frame:
Up to Day 778
Reported as:
Median · days
Time to Death or Permanent Ventilation
daysNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Time to Death or Permanent VentilationNA (NA to NA)NA (NA to NA)
SecondaryChange From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)

The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.

Time frame:
Baseline, Day 659
Reported as:
Geometric mean · ratio
Change From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)
ratioNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Change From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)0.13 (0.10 to 0.16)0.34 (0.01 to 10.79)
SecondaryChange From (Ratio to) Baseline in Plasma Levels of NF-L

The change from baseline data was reported in terms of geometric mean ratio to baseline. Lower ratios to baseline represent greater reductions in concentrations of NF-L from baseline.

Time frame:
Baseline, Day 778
Reported as:
Geometric mean · ratio
Change From (Ratio to) Baseline in Plasma Levels of NF-L
ratioNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Change From (Ratio to) Baseline in Plasma Levels of NF-L0.13 (0.10 to 0.17)0.29 (0.03 to 2.74)

Adverse events

Collected over From first dose of study drug up to end of study (up to Day 778). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nusinersen 2 SMN2 Copies1/42 (2.4%)24/42 (57.1%)38/42 (90.5%)
Nusinersen 3 SMN2 Copies0/4 (0%)2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Pneumonia moraxellaInfections and infestations0/421/4
Rhinovirus infectionInfections and infestations3/421/4
Tendinous contractureMusculoskeletal and connective tissue disorders0/421/4
PneumoniaInfections and infestations8/420/4
Acute respiratory failureRespiratory, thoracic and mediastinal disorders5/420/4
Parainfluenzae virus infectionInfections and infestations3/420/4
DehydrationMetabolism and nutrition disorders3/420/4
Developmental hip dysplasiaCongenital, familial and genetic disorders2/420/4
Metapneumovirus pneumoniaInfections and infestations2/420/4
Pneumonia viralInfections and infestations2/420/4
Most frequent other events
Showing 10 of 42
Most frequent other events
EventNusinersen 2 SMN2 CopiesNusinersen 3 SMN2 Copies
Upper respiratory tract infectionInfections and infestations14/421/4
PyrexiaGeneral disorders13/420/4
EosinophiliaBlood and lymphatic system disorders0/421/4
Ear painEar and labyrinth disorders1/421/4
Middle ear effusionEar and labyrinth disorders0/421/4
VomitingGastrointestinal disorders8/421/4
InfluenzaInfections and infestations5/421/4
NasopharyngitisInfections and infestations7/421/4
RhinitisInfections and infestations2/421/4
Viral upper respiratory tract infectionInfections and infestations6/421/4

Baseline characteristics

The Intent-to-Treat (ITT) set included all participants who received at least 1 dose of nusinersen in the study.

Age, Continuous
Age, Continuous(months)Nusinersen 2 SMN2 CopiesNusinersen 3 SMN2 CopiesTotal
Mean10.61 ± 6.09032.79 ± 3.25512.54 ± 8.627
Sex: Female, Male
Sex: Female, Male(Participants)Nusinersen 2 SMN2 CopiesNusinersen 3 SMN2 CopiesTotal
Female16117
Male26329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nusinersen 2 SMN2 CopiesNusinersen 3 SMN2 CopiesTotal
Hispanic or Latino404
Not Hispanic or Latino38442
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nusinersen 2 SMN2 CopiesNusinersen 3 SMN2 CopiesTotal
Race — American Indian or Alaska native000
Race — Asian011
Race — Black or African American314
Race — Native Hawaiian or other Pacific Islander000
Race — White36238
Race — Multiple101
Race — Not reported due to confidentiality regulations000
Race — Other202
08

Study locations

15 sites
  • Arkansas Children's Hospital Research Institute
    Little Rock, Arkansas 72202, United States
  • Stanford Neuromuscular Research
    Palo Alto, California 94304, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Oregon Health and Science University (OHSU)
    Portland, Oregon 97239, United States
  • Children's Hospital Philadelphia - Neurology
    Philadelphia, Pennsylvania 19104, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Children's Hospital of The King's Daughters
    Norfolk, Virginia 23510, United States
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Schneider Children's Medical Center
    Petah Tikva, 4920235, Israel
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, Milan 20133, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
  • Hospital Sant Joan de Déu
    Esplugues Del Llobregat, Barcelona 08950, Spain
  • Hospital Universitario La paz
    Madrid, 28046, Spain
09

References and documents

Publications

  • Proud CM, Finkel RS, Parsons JA, Masson R, Brandsema JF, Kuntz NL, Foster R, Li W, Littauer R, Sohn J, Fradette S, Youn B, Paradis AD; RESPOND Study Group. Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. J Clin Invest. 2025 Sep 16;135(22):e193956. doi: 10.1172/JCI193956. eCollection 2025 Nov 17. PubMed 40956616 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Oct 2025, 57 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 27, 2020
StartActual
Jan 4, 2021
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTotal Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score: how it is measured was reworded
Oct 30, 2026
Documents
Secondary outcomes
10 edited, 3 added, 1 description edited
What changed in the outcomes
  • EditedNumber of Participants withWith Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 778 → From first dose of study drug up to end of study (up to Day 778)
  • EditedNumber of Participants with Change fromWith Shifts From Baseline in Clinical Laboratory Parameters (Haematology Parameters)Time frame: Up to Day 778 → Baseline up to Day 778
  • EditedNumber of Participants with Change fromWith Shifts From Baseline in ElectrocardiogramsClinical Laboratory Parameters (ECGsBlood Chemistry Parameters)Time frame: Up to Day 778 → Baseline up to Day 778
  • EditedNumber of Participants with Change fromWith Shifts From Baseline in Vital SignsClinical Laboratory Parameters (Coagulation Parameters)Time frame: Up to Day 778 → Baseline up to Day 778
  • EditedNumber of Participants whoWho Achieved Motor Milestones as Assessed by World Health Organization (WHO) CriteriaTime frame: Up to Day 778 → Day 778
  • EditedChange fromFrom Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) ScoreTime frame: Up to Day 778 → Baseline, Day 778
  • EditedChange fromFrom Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) ScoreTime frame: Up to Day 778 → Baseline, Day 778
  • EditedChange fromFrom Baseline in Revised Upper Limb Module (RULM) ScoreTime frame: Up to Day 778 → Baseline, Day 778
  • EditedChange From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)Time frame: Up to Day 659 → Baseline, Day 659
  • EditedChange From (Ratio to) Baseline in Plasma Levels of NF-LTime frame: Up to Day 778 → Baseline, Day 778
  • AddedNumber of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)Time frame: Baseline up to Day 778
  • AddedNumber of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECGs)Time frame: Baseline up to Day 778
  • AddedNumber of Participants With Abnormalities in Vital SignsTime frame: Up to Day 778
  • DescriptionTime to Death or Permanent Ventilation: how it is measured was reworded
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTotal Hammersmith Infant Neurological Examination (HINE) Section 2 Motor Milestones Score: how it is measured was reworded
    Secondary outcomes 10 edited, 3 added, 1 description edited
    What changed in the outcomes
    • EditedNumber of Participants withWith Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 778 → From first dose of study drug up to end of study (up to Day 778)
    • EditedNumber of Participants with Change fromWith Shifts From Baseline in Clinical Laboratory Parameters (Haematology Parameters)Time frame: Up to Day 778 → Baseline up to Day 778
    • EditedNumber of Participants with Change fromWith Shifts From Baseline in ElectrocardiogramsClinical Laboratory Parameters (ECGsBlood Chemistry Parameters)Time frame: Up to Day 778 → Baseline up to Day 778
    • EditedNumber of Participants with Change fromWith Shifts From Baseline in Vital SignsClinical Laboratory Parameters (Coagulation Parameters)Time frame: Up to Day 778 → Baseline up to Day 778
    • EditedNumber of Participants whoWho Achieved Motor Milestones as Assessed by World Health Organization (WHO) CriteriaTime frame: Up to Day 778 → Day 778
    • EditedChange fromFrom Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) ScoreTime frame: Up to Day 778 → Baseline, Day 778
    • EditedChange fromFrom Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) ScoreTime frame: Up to Day 778 → Baseline, Day 778
    • EditedChange fromFrom Baseline in Revised Upper Limb Module (RULM) ScoreTime frame: Up to Day 778 → Baseline, Day 778
    • EditedChange From (Ratio to) Baseline in Cerebrospinal Fluid (CSF) Levels of Neurofilament Light Subunit (NF-L)Time frame: Up to Day 659 → Baseline, Day 659
    • EditedChange From (Ratio to) Baseline in Plasma Levels of NF-LTime frame: Up to Day 778 → Baseline, Day 778
    • AddedNumber of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)Time frame: Baseline up to Day 778
    • AddedNumber of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECGs)Time frame: Baseline up to Day 778
    • AddedNumber of Participants With Abnormalities in Vital SignsTime frame: Up to Day 778
    • DescriptionTime to Death or Permanent Ventilation: how it is measured was reworded
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04488133
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Jan 4, 2021
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nusinersen

Start the discussion